Simplex Trading’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
BC
DC
RA
Simplex Trading's LCTX Position: Q2 2026 in Review
Simplex Trading sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 9,698 shares — an estimated $13.4K sold.
Simplex Trading first reported a position in LCTX in Q2 2015 and held it in 31 quarters. The position peaked at $168K in Q1 2021. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Simplex Trading reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
- Simplex Trading sold 9,698 Lineage Cell Therapeutics shares in Q2 2026, an estimated $13.4K.
- Simplex Trading first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 31 quarters.
- Simplex Trading's Lineage Cell Therapeutics position peaked at $168K in Q1 2021.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.